Gland Pharma share price rose 2 percent in the opening trade on December 12 after the company received approval from the United States Food and Drug Administration (USFDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL single dose ampules.
At 09:21am, Gland Pharma was quoting at Rs 1,823.70, up Rs 48.35, or 2.72 percent, on the BSE.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vitamin KI Injectable Emulsion USP, 10 mg/mL, of Hospira, Inc.
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
The company expects to launch this product through its marketing partners in the near future.
Catch all the market action on our live blog
Earlier in this month, the company received USFDA approval for Latanoprost Ophthalmic Solution, 0.005%, which is used for the treatment of high eye pressure/intraocular pressure (IOP) in patients with openangle glaucoma or ocular hypertension.
The company's consolidated Q2FY25 profit declines 15.7 percent to Rs 163.5 crore, while revenue grows 2.4 percent to Rs 1,405.8 crore, YoY.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
